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In recent clinical studies, vascular disrupting agents (VDAs) are mainly used in
combination with chemotherapy. However, an often overlooked concern in treatment
combination is the VDA-induced impairment of chemotherapy distribution in the tumor.
The work presented here investigated the impact of blood flow shutdown induced by
Combretastatin A4 (CA4) on gemcitabine uptake into mouse hepatocarcinoma. At 2 h
after CA4 treatment, using DCE-MRI, a significant decrease in the perfusion-relevant
parameters Ktrans and Vp were observed in treated group compared with the control
group. The blood flow shutdown was indeed confirmed by a histology study. In a third
experiment, the total gemcitabine uptake was found to be significantly lower in treated
tumors, as assessed in a separate experiment using ex vivo fluorine nuclear magnetic
resonance spectroscopy. The amount of active metabolite gemcitabine triphosphate was
also lower in treated tumors. In conclusion, the blood flow shutdown induced by VDAs
can impact negatively on the delivery of small cytotoxic agents in tumors. The present
study outlines the importance of monitoring the tumor vascular function when designing
drug combinations.
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INTRODUCTION
Tumor vasculature is an attractive target in anticancer therapy because of its critical role in tumor
growth, development, and metastasis (Folkman, 1995). Moreover, the unique characteristics of
tumor vasculature compared with that of normal tissue can be selectively exploited by antivascular
therapies. Unlike antiangiogenic agents, which prevent the development of new blood vessels,
vascular disrupting agents (VDAs) target the established tumor vasculature causing a rapid collapse
in tumor blood flow leading to secondary extensive tumor necrosis (Thorpe, 2004; Tozer et al.,
2005). Several preclinical studies have shown that VDAs induce necrosis in the poorly perfused core
regions but spare tumor cells in periphery (Blakey et al., 2002; Chaplin and Hill, 2002; Siemann,
2011). This “viable rim” forms the rationale for combination approaches since VDAs affect the
central part of the tumor that is often resistant to conventional therapies, whereas conventional
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treatments are more active on highly proliferating and well
oxygenated peripheral cells (Tozer et al., 2008). Consequently,
VDAs are mainly used in combination with chemotherapy in
current clinical studies.
However, an often overlooked concern is the possible VDA-
induced impairment of drug distribution in the tumor (Cesca
et al., 2013). Indeed, currently, combination strategies are
often empirical whereas a careful sequence and schedule of
administration of treatments are needed to avoid negative
interactions and to potentiate synergic efficacy of the drugs
(Wang et al., 2012; Cesca et al., 2013). In this context, early
biomarkers of response are needed to assess the impact of VDA
on chemotherapy delivery and to determine optimal timing
of administration in early clinical trials. Dynamic contrast-
enhanced magnetic resonance imaging (DCE-MRI) is the
imaging method of choice to assess early microvascular changes
induced by antivascular treatments (O’Connor et al., 2012). It
generates non-invasive maps of hemodynamics parameters such
as blood flow and/or vascular permeability. Moreover, it has been
suggested that DCE-MRI with lowmolecular weight gadolinium-
based contrast agents can be used to predict the delivery of drugs
with similar size to the interstitium of solid tumors (Artemov
et al., 2001).
The first aim of the present work was to investigate how
a negative modulation of tumor blood flow could affect the
uptake of chemotherapeutic agents into the tumor. A second
objective was to appraise the potential of DCE-MRI to predict the
impact of the modulation of tumor perfusion on chemotherapy
delivery. To that purpose, we first monitored the early effects of
Combretastatin A4 (CA4), the lead compound of VDAs, using
DCE-MRI. CA4 acts as a tubulin-binding agent, leading to a
destabilization of the tubulin polymers of the cytoskeleton of
proliferating endothelial cells. This way, an acute increase in
tumor vascular permeability is induced, which in turn triggers
several changes that together, decrease blood flow (Tozer et al.,
2005). The perfusion parameters Ktrans (the volume transfer
constant between blood plasma and extravascular extracellular
space) and Vp (the blood plasma volume fraction) were
determined since it has been previously shown to be relevant
markers of CA4 efficacy (Maxwell et al., 2002; Nielsen et al.,
2010). To corroborate MRI findings, a qualitative histology
study was conducted in a separate group of animals to assess
the perfusion using the Hoescht 33342 marker. In parallel, the
uptake of the fluorinated chemotherapeutic agent gemcitabine
was assessed ex vivo using fluorine nuclear magnetic resonance
spectroscopy (19F NMR).
MATERIALS AND METHODS
Animals and Tumor Model
Transplantable liver tumors (TLT hepatocarcinoma Taper et al.,
1966) were induced i.m. into the right gastrocnemius muscle
of 5-week-old male NMRI mice (Janvier, France). Tumors were
allowed to reach up to 8 ± 0.5mm in diameter prior to
experimentation. For all experiments, mice were anesthetized
using isoflurane (3% for induction, 1.5% for maintenance, mixed
with air). Body temperature was maintained at 37.0 ± 1.0◦C
with a circulating water blanket and monitored together with
respiration rate during experiments. All animal experiments were
performed in accordance to national animal care regulations
with the approval of local Ethics Board 2010/UCL/MD/01. CA4
(Sigma-Aldrich, Belgium) dissolved in DMSO was delivered i.p.
at a dose of 100mg/kg (Grosios et al., 1999).
19F NMR and DCE-MRI experiments were performed on
separate cohorts of mice, because of the possible influence of the
contrast agent on fluorine relaxation times (Ratner et al., 1989).
DCE-MRI
Mice were divided into an untreated control group receiving
vehicle (DMSO) (n= 6) and another treated group receiving CA4
(n= 6). DCE-MRI acquisitionwas carried out 2 h after treatment,
a timing for which we anticipated an important reduction in
tumor perfusion (Thorpe, 2004). The contrast agent (CtAg) used
was gadoterate meglumine, a small gadolinium chelate routinely
used in clinics (0.286mmol Gd/kg). A 24G catheter was inserted
in the caudal vein of mice for CtAg injection.
Acquisition
A quadrature whole body coil was used for radiofrequency
transmission and reception. High-resolution multi-slice T2-
weighted spin echo anatomical imaging was performed just
before DCE-MRI. For DCE-MRI, T1 weighted gradient echo
images were obtained with a fast low angle shot sequence with the
following parameters: repetition time= 15ms, echo time= 2.074
ms, flip angle = 40◦, matrix = 128 × 64, field of view = 40 ×
40mm, zero-fill acceleration factor = 1.4. A first set of 400 scans
with a temporal resolution of 1.19 s was acquired, with CtAg
manually administered intravenously after the twentieth scan
over 2 s. Afterwards, a slower DCE data set was acquired with
a temporal resolution of 10.1 s to monitor the CA washout (300
images). A proton density weighted image was acquired before
T1-weighted sequences with the following parameters: repetition
time = 3500 ms, echo time = 2.074ms, flip angle = 40◦, matrix
= 128× 64, field of view= 40× 40mm.
Data Analysis
DCE-MRI data were analyzed using the extended Tofts model
(ETM). A population-averaged arterial input function was used,
previously obtained in iliac artery/vein of the same mouse model
(Fruytier et al., 2014a). A global region of interest (ROI) was
manually delineated to cover the entire tumor area (using the
T2-weighted anatomical images as reference).
The signal intensity obtained from the FLASH sequence is



















where S0 is a scaling factor comprising proton density and
instrumental factors and is determined by the proton density
sequence, α is the flip angle, TR is the repetition time, and TE
is the echo time. Signal dependence on T2
∗ was neglected due to
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the short echo time (TE = 2.074 ms). In tumors, the relationship
between relaxation rate (1/T1) and CA concentration can be






+ r1 · C (t) , (2)
where r1 is the longitudinal relaxivity of the CA at 11.7T, T10 is
the longitudinal relaxation time in the absence of the CA, and
C(t) is the concentration of CA in tissue.
The measured tumor concentration time course [Ct(t)] of
pixels was individually fitted to the ETM using a Levenberg-









+ vp · D ·
2∑
i= 1
ai · exp(−mit), (3)
where Ktrans is the volume transfer constant between blood
plasma and extravascular extracellular space (EES) [min−1], vp
is the blood plasma volume per unit volume of tissue, and kep is
the rate constant between EES and blood plasma [min−1] (Tofts
et al., 1999). D is the CA bolus dose. The constants ai and mi are
population-averaged mean amplitudes and decay rates obtained
previously in same tumor model: a1 = 16.41; m1 = 11.20; a2 =
8.41; m2 = 0.27 (Fruytier et al., 2014a). Some pixels provide
nonphysiological values of Ktrans (Ktrans < 0, Ktrans > 1min−1)
and/or vp (vp < 0, vp > 1). For mean calculations, these pixels
were set to zero or 1 respectively.
Ex vivo 19F NMR
All mice received gemcitabine (800 mg/kg, IP injection, Hospira)
2 h after vehicle (n = 6) or CA4 treatment (n = 6). Tumors were
carefully excised 2 h after gemcitabine treatment and snap-frozen
for ex vivo 19F NMR experiments.
Tissue Extraction
The following protocol was adapted from Refs (Olive et al.,
2009; Bapiro et al., 2011). The snap-frozen tumors were weighted
and homogenized in four volumes of ice-cold acetonitrile for
5min. An equal volume of ice-cold water was added and
homogenization was carried on for a further 5 min. Samples were
incubated on ice for 10min before being centrifuged at 14,000 g
for 10min at 4◦C. The supernatants were transferred to vials and
stored at−80◦C before lyophilization.
Acquisition
The Freeze-dried tumor supernatants were re-suspended in
500 µl of deuterium oxide (D20), spiked with 185 nmoles
of 2-Fluoro-2′-deoxyadenosine (2F2dA), used as the external
standard.
19F NMRmeasurements were carried out on a Bruker Avance
II NMR spectrometer operating at 300MHz for 1H and fitted
with a 5mm BBFO probe. 1D 19F spectra were acquired using
inverse gated 1H decoupling with the following parameters:
sweep width of 201 ppm, 3500 scans, acquisition time of 0.3 s,
and a delay between scans of 4 s, resulting in a total measurement
time of 4 h and 10 min. NMR tubes were spun at 20Hz in
the spectrometer to ensure sample homogeneity and short 1D
1H spectra were acquired prior to 19F measurements to ensure
decent field homogeneity was achieved. Gain settings were kept
the same for all measurements. Chemical shifts were ascertained
for all components by spiking an untreated homogenate with
the appropriate standards. Chemical shift referencing for 19F was
CCl3F as stated in the IUPAC recommendations (Harris et al.,
2002). Processing parameters prior to Fourier transformation
included a 15Hz line broadening and a backwards linear
prediction in order to eliminate the broad signal due to the 19F
background from the probe (40 points were back-predicted).
Data Analysis
We integrated all observed fluorine peaks of gemcitabine and
metabolites, using the Bruker TOPSPIN software. Two integrals
were measured: one for the reference 2F2dA and the other
encompassing gemcitabine and its metabolites. We normalized
the integrals to the tissue wet weights in order to obtain total
gemcitabine metabolite concentration in samples in µg/mg
tissue.
FIGURE 1 | Typical signal enhancement following contrast agent injection observed in tumor (A) and in muscle (B) of a control mouse (dark solid line) and a
treated mouse (gray dotted line). (A) A smaller enhancement and a slower washout were typically observed in treated compared to untreated tumors. (B) By contrast,
the enhancement pattern was similar in muscle of control and treated mice.
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FIGURE 2 | (A) Absolute values of pharmacokinetic parameters Ktrans for control and treated tumors. A significant Ktrans decrease was observed in treated tumors
compared to untreated ones (Mann-Whitney test; **p < 0.01). (B) Values of Vp (plasma volume fraction) for control and treated tumors. A significant decrease in Vp
was observed in treated tumors compared to untreated ones (Mann-Whitney test; **p < 0.01).
FIGURE 3 | Representative pictures of tumor sections from untreated
and CA4-treated mice stained with CD31 antibody for endothelial cells
(red). High (bar = 500µm) and low (bar = 50 µm) magnifications are
presented. The Hoechst 33342 perfusion marker was administered 2min
before sacrifice. Treated tumors (B,D) showed less perfused vessels (blue)
compared to untreated tumors (A,C).
Histology
Six NMRI tumor-bearing mice were treated with vehicle (n =
3) or CA4 (n = 3). Two hours after treatment, the functional
perfusion marker Hoechst 33342 (15 mg/kg; iv injection; Sigma-
Aldrich) was injected. Mice were sacrificed 2 min later. Five
micrometer tumor cryosections were immunostained with a
rat monoclonal antibody against CD31 (BD, clone MEC 13.3)
and revealed with Alexa568 conjugated anti-rat secondary
antibodies (Invitrogen). Tumor sections were imaged using a
Zeiss Axioimager Z1 fluorescent microscope equipped with an
Apotome module (Zeiss, Wetzlar, Germany).
Estimation of CA4-induced cell death was also obtained
from TLT tumor-bearing mice treated with CA4 (n = 7)
or vehicle (n = 8). Tumors were excised at day 1 after
treatment initiation. Tumors were embedded in Tissue-Tek
OCT compound and frozen in liquid nitrogen-cooled isopentane
for cryosectioning. Samples were cut into 5µm sections. The
frozen slices were stained with Haematoxylin & Eosin or
were probed for cellular death by TUNEL assay using an
in situ cell death detection kit (Roche Diagnostics, Belgium).
For TUNEL assay, nuclei were also counterstained with
Hoechst 33342. Slides were then scanned with a Zeiss Mirax
fluorescence microscope. Cell death was quantified using Frida
software and expressed as a percentage of the whole tumor
area.
Statistical Analysis
Values are presented as mean ± standard error, unless otherwise
stated. All statistical analysis was performed with GraphPad
Prism 5. Non parametric Mann-Whitney tests were used to
compare mean changes between control and treated groups. P <
0.05 are considered statistically significant.
RESULTS
CA4 Treatment Induced an Early Decrease
in Tumor Blood Flow in TLT Tumors
Figures 1, 2 illustrate DCE-MRI findings. DCE-MRI consists of
the acquisition of T1-weighted images before, during, and after
a contrast agent administration allowing for the generation of
a signal intensity-time course from a tissue of interest. Figure 1
shows examples of enhancement curves (percentage of signal
enhancement vs. time of selected region of interest) obtained
from tumor (Figure 1A) andmuscle (Figure 1B) of a control and
a treated mouse. A smaller enhancement and a slower washout
were typically observed in treated compared to untreated tumors
(Figure 1A). By contrast, the enhancement pattern was similar in
muscle of control and treated mice (Figure 1B).
The pharmacokinetic modeling of pixel signal intensity-
time curve allowed extracting Ktrans and Vp for each pixel.
Mean tumor Ktrans and Vp were calculated for each mouse by
averaging all pixel values (Figure 2). A significant Ktrans decrease
was observed in treated tumors compared to untreated tumors
(0.11 vs. 0.36min−1; ∗∗p < 0.01; Figure 2A). Ktrans values were
lower in treated mice, particularly in tumor core regions. A
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FIGURE 4 | Measurement of cellular death by quantification of Hematoxylin Eosine staining (A) and of TUNEL assay (B) in control and in CA4-treated
tumors at day 1. Data are expressed as means ± SEM (Unpaired t-tests; **p < 0.01, ***p < 0.001).
FIGURE 5 | 19F NMR findings. (A) Typical spectra obtained from 3 treated (in black) and 3 untreated (in red) tumor homogenates. Gemcitabine (dFdC) and two of its
metabolites, 2′,2′-difluorodeoxyuridine (dFdU) and gemcitabine triphosphate (dFdCTP), were identified on the spectra. The metabolite dFdCTP was absent (or present
in smaller quantities) in treated tumors. (B) Total gemcitabine uptake was quantified using an integral encompassing gemcitabine and its metabolites. A significant
decrease of total gemcitabine uptake was observed in treated tumors when compared with untreated ones (Mann-Whitney test; **p < 0.01).
significant Vp decrease was also observed in treated tumors
compared to untreated tumors (0.099 vs. 0.552; ∗∗p < 0.01)
(Figure 2B).
Histology confirmed the blood flow shutdown seen by DCE-
MRI induced by CA4 treatment (Figure 3). Treated tumors
(Figures 3A,C) showed less perfused vessels (assessed with
Hoechst 33342, administered 2 min before sacrifice) compared
to untreated tumors (Figures 3B,D). No difference was visually
observed between groups in vascular density (assessed with
CD31 antibody). We also observed an increase in tumor cell
death 1 day after CA4 treatment. Histological analysis of
Haematoxylin/Eosin -stained slices showed that tumors treated
with CA4 present enlarged necrotic regions (54 ± 9%) as
compared with tumors treated with vehicle (20 ± 3%) (∗∗p <
0.01) (Figure 4A). On the other hand, using the TUNEL assay
(Figure 4B), positively stained areas were increased in treated
tumors compared to control tumors (10 vs. 30%; ∗∗∗p < 0.001;
Figure 4B).
CA4 Treatment Induced a Decrease of
Gemcitabine Uptake in TLT Tumors
In ex vivo 19F NMR experiments, gemcitabine parent
compound (dFdC) and two of its metabolites, 2′,2′-
difluorodeoxyuridine (dFdU) and gemcitabine triphosphate
(2,2′-difluorodeoxycytidine-5′-triphosphate-dFdCTP) were
identified. Typical spectra are shown on Figure 5A. We
quantified the total gemcitabine amount using an integral
encompassing gemcitabine and its metabolites. A significant
decrease of total gemcitabine amount was observed in
treated tumors when compared with untreated ones (0.07
vs. 0.22µg/mg of tissue; ∗∗p < 0.01; Figure 5B). Chemical shifts
were determined by spiking an untreated tumor homogenate
with appropriate standards. Results are shown on Figure 6.
Respective assignments in 19F NMR spectra were −54.6 ppm
for external standard 2F2dA, −118.7 ppm for dFdC, two
doublets at −118.2 and −119.25 ppm (J = 241Hz; i.e., four
frequency lines at −117.8, −118.6, −118.8, and −119.7 ppm)
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FIGURE 6 | (A) 1D 19F spectrum of a control tumor homogenate (800 mg/kg
gemcitabine). (B–D) 1D 19F spectra of an untreated homogenate spiked
successively with 100 nmoles of dFdC (B), dFdCTP (C), dFdU (D). Each
spectrum is overlaid on the spectrum of the control tumor homogenate
shown in (A).
for dFdU, and a doublet at −119.25 ppm (J = 15Hz) for
dFdCTP. One can observe that the metabolite dFdCTP was
present in smaller quantities in treated tumors compared to
untreated tumors (Figure 5). For quality assurance purpose,
we measured the area under the curve of the external standard
2F2dA for each sample and observed that it was stable from
experiment to experiment, with a standard deviation of < 5% of
the mean.
DISCUSSION
In this work, we demonstrate that a negative modulation of
tumor blood flow by CA4 treatment causes a significant decrease
in gemcitabine delivery in a solid tumor mouse model. It outlines
the need to assess the impact of treatments on the tumor vascular
function, for instance using DCE-MRI, when appraising a novel
drug combination.
CA4 acts as a tubulin-binding agent, leading to a
destabilization of the tubulin polymers of the cytoskeleton
of proliferating endothelial cells. This way, an acute increase in
tumor vascular permeability is induced, which in turn triggers
several changes that together, decrease blood flow (Tozer et al.,
2005). DCE-MRI confirmed the blood flow shutdown at 2 h after
CA4 treatment, as revealed by reduced enhancement patterns as
well as Ktrans and Vp decrease in treated tumors, in comparison
to untreated ones (Figure 2). The parameter Ktrans represents
the rate of transfer of the CtAg from the blood to the interstitial
space. The physiological interpretation depends on the balance
between capillary permeability and blood flow in the tumor:
higher permeability makes Ktrans more reflective of blood flow
(flow-limited situation), whereas lower permeability makes Ktrans
more reflective of vascular permeability (permeability-limited
situation; Tofts et al., 1999; O’Connor et al., 2007; Zweifel
and Padhani, 2010). However, we previously reported that, in
case of VDA assessment, Ktrans changes determined with small
molecular weight CtAg are more reflective of tumor blood flow
changes, due to the high permeability of the CtAg across the
capillary membrane (corresponding to a flow-limited situation;
Fruytier et al., 2014b). Here, the observed Ktrans decrease
(Figure 2A) can thus be related to the early tumor blood
flow shutdown induced by CA4, as confirmed by histology.
The observed decrease in Vp (Figure 2B), the plasma volume
fraction, is also consistent with the tumor blood flow shutdown.
Of note, histological studies confirmed that CA4-treated tumors
were less perfused compared to untreated tumors (Figure 3). As
a consequence of this blood flow shutdown, we also observed that
tumors treated with CA4 present more necrotic and apoptotic
areas 24 h post-treatment (Figure 4).
In a second step, we investigated how the induced tumor
blood flow shutdown can impact the delivery of chemotherapy,
using ex vivo 19F NMR spectroscopy to determine the levels of
gemcitabine and its major metabolites in tumors. Gemcitabine
is a prodrug that must be phosphorylated intracellularly by
deoxycytidine kinase to exhibit cytotoxic activities. Its major
intracellular active metabolite is dFdCTP, although it remains
in a constant ratio with gemcitabine monophosphate and
diphosphate (Heinemann et al., 1992). Gemcitabine is inactivated
mainly by deoxycytidine deaminase mediated conversion to
dFdU (Mini et al., 2006). The 19F NMR experiments showed
that the total gemcitabine uptake into the tumor was significantly
lower in treated mice (CA4+gemcitabine) compared to controls
(vehicle+gemcitabine) (Figure 5). These results are in line with
those of Kristjansen et al. which demonstrated in ex vivo
perfused human small cell lung cancer that the initial intratumor
distribution of dFdC is flow dependent (Kristjansen et al., 1996).
Gemcitabine, its three phosphorylated metabolites and dFdU
overlap in 19F spectrum, making accurate quantification for
individual metabolites difficult (Blackstock et al., 2001). However,
it is clear that the intensity of the peak of the most active
metabolite dFdCTP was lower in treated tumors compared to
controls, or in some cases, null.
Several studies reported that blood flow reductions following
VDA treatment could potentiate chemotherapy efficacy by
trapping chemotherapy within the tumor and consequently
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increasing tumor exposure to the drug (Siim et al., 2003;
Siemann, 2011). This has been observed for combinations
where VDA was given after chemotherapy but also for
VDA given before chemotherapy. For instance, Pruijn
et al reported that the administration of the antivascular
agent 5,6-dimethylxanthenone-4-acetic acid 2 h before the
chemotherapeutic agent melphalan leads to an increase of
the alkylating agent levels in the tumor and consequently
to an enhanced activity (Pruijn et al., 1997). Additional
studies reported that concurrent administration of VDA and
chemotherapy increased antitumor activity (Morinaga et al.,
2003; Kleespies et al., 2005).
However, as outlined in the present work, the induced blood
flow shutdown could also decrease drastically the delivery of
the chemotherapeutic agent inside the tumor. The potentiation
of chemotherapy by drug trapping will take place only if the
chemotherapeutic agent can reach the tumor before the vascular
shutdown. Predictive biomarkers of drug delivery could thus
be particularly useful in assessing novel drug combinations. For
that purpose, we appraised the potential of DCE-MRI using low
molecular weight CtAg which could mimic small conventional
cytotoxic drugs in such a way that their delivery inside the tumor
could be reflective of uptake and distribution of conventional
chemotherapy (Artemov et al., 2001). In addition to be a
pharmacodynamic biomarker of CA4 treatment, the DCE-MRI
parameter Ktrans was predictive of the gemcitabine delivery. We
observed a similar decrease of Ktrans and gemcitabine delivery
in the parallel groups of mice (70 and 68.7% of decrease,
respectively).
Response to chemotherapy is determined by the delivery
of cytotoxic agent to the tumor but also by chemotherapy
cellular uptake, retention, and metabolic activation, as well as by
chemotherapy sensitivity in the target tumor cells (van Laarhoven
et al., 2007; Jain, 2012). Moreover, in addition to any spatial
cooperation between both treatments, final outcome following
treatment combination will be also affected by the effect of the
VDA on the tumor (cell/vasculature; Wang et al., 2012). The
microenvironmental changes secondary to VDA-induced blood
flow shutdown can also modulate the sensitivity of chemotherapy
(Pruijn et al., 1997; Siim et al., 2003). Indeed, on the one hand,
hypoxia and acidosis could be favorable to the activity of specific
agents (e.g., bioreductive drugs, melphalan; Pruijn et al., 1997;
Taraboletti et al., 2010), whereas, the severe glucose and oxygen
deprivation induced by CA4P have been shown to induce GRP78
expression that could lead to drug resistance (Dong et al., 2005).
Our study could be considered as a proof-of-concept that
directly links the effect of VDA on the blood flow to the delivery
another chemotherapeutic agent. A limitation of our study is
that we analyzed this effect only at one timing (2 h) post-VDA
treatment. For the future, it could be interesting to follow the
dynamics of this effect at different timings and to study the
impact of the combination at different timings on the tumor
response to treatments.
In conclusion, although the link between drug delivery and
therapeutic efficiency is not straightforward, the present study
demonstrates that the potential impact of VDA on intratumoral
drug delivery should be taken into account when designing
novel drug combination. For that purpose, the assessment of
tumor vascular function by DCE-MRI could be helpful to avoid
misinterpretation when a failure of treatment is observed, but
also to maximize therapeutic gain.
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